Asha Therapeutics Announces the Presentation of New Data on ASHA-1007, a Novel VHL Recruiter for TPD

NOVEL THERAPIES FOR TOMORROW'S CURES
THE SCIENCE
At Asha Therapeutics we are developing novel, first-in-class compounds targeting the point of greatest therapeutic impact for diseases with high unmet medical need. We have active programs in neuroscience for therapeutic intervention in neurodegenerative diseases including Parkinson's Disease (PD), Alzheimer's Disease (AD), and Amyotrophic Lateral Sclerosis (ALS), post-viral illnesses such as Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long Haul COVID, as well as Ischemic Stroke and Neuro-oncology.

Neuro-centric Focus
Nearly 1 in 6 people, over 1 billion globally suffer from neurological disorders... our goal is to change that. We are focused on developing novel therapeutics for diseases with high unmet medical need
PARKINSON'S DISEASE | ALZHEIMER'S DISEASE
STROKE | AMYOTROPHIC LATERAL SCLEORIS